ADVANCED COMPREHENSIVE MAGNETIC RESONANCE SOLUTION FOR THE NONINVASIVE CHARACTERIZATION OF HIGH RESOLUTION METABOLIC BIOMARKERS OF RISK IN PATIENTS WITH ALZHEIMER'S DISEASE AND DEMENTIA

先进的综合磁共振解决方案，用于无创表征阿尔茨海默病和痴呆症患者风险的高分辨率代谢生物标志物

• 批准号: 10820517
• 负责人: Ravi Srinivasan
• 金额: $ 56.99万
• 依托单位: ADVANCED IMAGING RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10820517
• 关键词: 3-Dimensional; Address; Age; Aging; Agreement; Alzheimer disease detection; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Alzheimer’s disease biomarker; Atrophic; Binding; Bioenergetics; Biological Markers; Brain; Calibration; Clinical; Clinical Trials; Computer software; Custom; Data; Dementia; Development; Devices; Dimensions; Disease Progression; Early Diagnosis; Elderly; Energy Metabolism; Exhibits; Functional Magnetic Resonance Imaging; Goals; Head; Human; Image; Licensing; Link; Magnetic Resonance; Magnetic Resonance Imaging; Maps; Marketing; Measurable; Measurement; Medial; Medical; Mental disorders; Metabolic; Metric System; Minor; Mitochondria; National Institute on Aging; Nicotinamide adenine dinucleotide; Noise; Nuclear; Patients; Pennsylvania; Performance; Phase; Play; Procedures; Process; Protocols documentation; Reproducibility; Research; Research Personnel; Resolution; Risk; Satiation; Scanning; Signal Transduction; Small Business Innovation Research Grant; Spectrum Analysis; Structure; Symptoms; System; Technology; Temporal Lobe; Testing; Time; Tissues; Training; United States National Institutes of Health; Universities; Validation; Vendor; Visualization; Work; absorption; clinical application; commercialization; data acquisition; design; detector; diagnostic tool; high risk; improved; innovation; medical schools; memory process; metabolomics; mild cognitive impairment; nervous system disorder; novel; predictive marker; programs; quality assurance; radio frequency; risk prediction; screening; software development; spectrograph; transmission process

NIH SBIR Fast-Track, PAS-22-196 Advanced Comprehensive Magnetic Resonance Solution for the Non Invasive Characterization of No Clinical Trials High Resolution Metabolic Biomarkers of Risk in Patients with Alzheimer’s Disease and Dementia Project Summary This project addresses the Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Initiative of the National Institute on Aging (PAS-22-196). We propose to develop an advanced hardware-software package, ADRD360, to optimally acquire, process, and analyze magnetic resonance imaging (MRI) and spectroscopy (MRS) in the human brain. The ADRD360 will help to localize metabolic signatures and obtain MRI and MRS brain data at much higher resolutions than currently possible on clinical MR systems. Highly resolved MRI and MRS will be of utmost importance to aid in the early prediction of the risk of developing AD. The ADRD360 may lead to the early detection of structural and metabolic parameters as predictive diagnostic tool biomarkers in patients with AD, ADRD, other neurological disorders and psychiatric diseases. This project will offer a complete solution with the development and optimization of 1) advanced radio-frequency (RF) coils approaching ultimate intrinsic signal-to-noises (UISNRs) and acceptable specific absorption rates (SARs); 2) pushing structural MR imaging resolutions over commercial devices; 3) advancing shimming procedures to improve the homogeneity of the B0 field; 4) permitting high-resolution, multi-dimensional, multi-volume MRS exams with 100% structure-function correlation in reasonable scan times; 5) a stand-alone, easy-to-use program that provides the crucial link between multi-dimensional structural and multi-volume MRS acquisition, including its clinical and metabolic interpretation by effectively tackling the demanding spectral processing and analysis needs; and 6) a comprehensive MRI-MRS metrics system calibration, quality assurance and validation phantom essential to confirm reproducibility of measurements. Initially, we will demonstrate the research utility and clinical applicability by determining the structural and metabolic MRI-MRS parameter spread in healthy subjects. Results from this study will become essential to interpretation in subjects at higher risk of developing AD. This work builds upon our expertise in creating the first commercial dual- tuned 1H-31P 1.5T and 3T head coils (R44NS037273). This research also builds upon our work with the development of an automated B0 shimming program (FWHM 11.7 ± 1.9 Hz, n=94 at 1.5T) and the interactive MRS software. This project will offer 'A Complete Solution for the Early AD Detection’ with advanced brain MR assessments in the high-resolution structural and functional MRI exams, and multinuclear metabolic-based MRS acquisitions. Our licensed Siemens vendor agreement will propel the development and commercialization of the ADRD360. We aim to satiate the researchers by approaching the ultimate intrinsic SNR 31P and 1H limits on the 3T and 7T MR systems. We plan to demonstrate the clinical advantages by identifying critical structural and metabolic MR brain parameters that can be used as screening biomarkers in humans with mild cognitive impairment due to aging, AD, and related dementia. Confidential Proprietary Information Advanced Imaging Research dba SREE Medical Systems

NIH SBIR快速轨道，PAS-22-196，用于非侵入性表征的高级综合磁共振解决方案 没有临床试验在阿尔茨海默氏病和痴呆症患者中高分辨率的代谢生物标志物 项目摘要 该项目涉及有关阿尔茨海默氏病（AD）和广告相关痴呆症的前进研究 （ADRD）国家老化研究所的倡议（PAS-22-196）。我们建议开发高级 硬件软件软件包ADRD360，以最佳获取，处理和分析磁共振 人脑中的成像（MRI）和光谱法（MRS）。 ADRD360将有助于定位代谢 签名并以比目前可能更高的分辨率获得MRI和MRS脑数据 临床MR系统。高度解决的MRI和太太将非常重要 预测开发广告的风险。 ADRD360可能会导致结构和 代谢参数是AD，ADRD患者的预测诊断工具生物标志物 神经系统疾病和精神病。该项目将提供完整的解决方案 开发和优化1）接近最终内在的高级射频（RF）线圈 信噪比（UISNR）和可接受的特定滥用率（SARS）； 2）推动结构MR 对商业设备的成像分辨率； 3）推进改进的光滑程序 B0场的同质性； 4）允许高分辨率，多维的多卷MRS考试 在合理的扫描时间中具有100％的结构功能相关性； 5）独立的，易于使用的程序 这提供了多维结构和多卷MRS采集之间的关键联系， 通过有效解决苛刻的光谱处理，包括其临床和代谢解释 和分析需求； 6）全面的MRI-MRS指标系统校准，质量保证和 验证幻影对于确认测量的可重复性必不可少。最初，我们将证明 研究实用程序和临床适用性通过确定结构和代谢MRI-MRS参数 在健康的受试者中传播。这项研究的结果对于对受试者的解释至关重要 开发广告的风险更高。这项工作以我们创建第一个商业双重的专业知识为基础 调谐1H-31P 1.5T和3T头线圈（R44NS037273）。这项研究还基于我们与 开发自动化的B0光滑程序（FWHM 11.7±1.9 Hz，n = 94，在1.5T时）和 交互式MRS软件。该项目将提供“早期广告检测的完整解决方案” 高分辨率结构和功能性MRI检查中的高级大脑MR评估，以及 基于多核代谢的MRS收购。我们的持牌西门子供应商协议将推动 ADRD360的开发和商业化。我们的目标是通过接近研究人员 3T和7T MR系统上的最终内在SNR 31p和1H限制。我们计划证明 通过识别可使用的关键结构和代谢MR脑参数来获得临床优势 作为筛查因衰老，AD和相关痴呆而导致的轻度认知障碍的人类的生物标志物。 机密专有信息高级成像研究DBA SREE医疗系统